CAS: 56310-20-4; Di-Tert-Butyl(Methyl)Silane

上下游产品

CAS号18395-90-9 二叔丁基氯硅烷 | CAS号917-54-4 甲基锂 | CAS号56310-18-0 二叔丁基氯硅烷 | CAS号75-54-7 甲基二氯硅烷 | CAS号594-19-4 叔丁基锂 | CAS号105866-92-0 [ditert-butyl(m... | CAS号103457-88-1 azido-ditert-bu...

📜甲基二氯硅烷,叔丁基锂 以 正戊烷 作为反应溶剂,化学反应 48.0H,以86%的收率获得产物二叔丁基甲基硅烷
参考文献:29 Si NMR 光谱作为 S-和 F-嵌段金属 (II)-硅烷键共价的探针
标题:29 Si NMR 光谱作为 S-和 F-嵌段金属 (II)-硅烷键共价的探针
摘要:我们报告了使用29 Si NMR 光谱和 Dft 计算组合来衡量 S-和 F-嵌段金属-硅键化学键合的共价性.配合物 [m(Si T Bu 3) 2 (Thf) 2 (Thf) X] (1-M : M = Mg,Ca,Yb,X = 0; M = Sm,Eu,X = 1) 和 [m (Si T Bu 2 Me) 2 (Thf) 2 (Thf) X] (2-M : M = Mg,X = 0; M = Ca,Sm,Eu,Yb,X = 1) 已被合成和表征.dft 计算和1-M和2-M 的29 Si NMR 光谱分析(m = Mg,Ca,Yb,No,由于实验不可用,最后在硅中)连同已知的 {si(Sime 3) 3 }--,{si(Sime 2 H) 3 }--和 {siph 3 }--取代的类似物提供了 20 个具有代表性的例子,涵盖了五个硅烷配体和四个二价金属,揭示了金属结合的29
DOI:10.1021/jacs.1C03236

专利信息

专利号:US-2012215002-A1
优先权日:2009-10-09
标 题:Synthesis of optically active intermediate for the preparation of montelukast
发明人：LEFORT LAURENT
权利人:LEFORT LAURENT
摘要:The present invention relates to the synthesis of optically active alcohols by means of enantioselective hydrogenation of ketones in biphasic systems. In particular the present invention relates to the synthesis of an optically active alcohol of general formula (1).

专利号:US-10053406-B2
优先权日:2015-10-23
标题 :Synthesis of honokiol
发明人：JARACZ STANISLAV; KOZLOWSKI MARISA; EUN LEE YOUNG; KIM SUN MIN
权利人:COLGATE PALMOLIVE CO; UNIV PENNSYLVANIA
摘要:Disclosed herein are improved methods for the synthesis of honokiol, as well as methods for the synthesis of 3,3′-di-tert-butyl-5,5′-dimethyl-[1,1′-biphenyl]-2,4′-diol, 3′,5-dimethyl-[1,1′-biphenyl]-2,4′-diol, and 2,4′-dimethoxy-3′,5-dimethyl-1,1′-biphenyl, 3,3′,5,5′-tetra-tert-butyl-[1,1′-biphenyl]-2,4′-diol, and certain tetrasubstituted bisphenols, and uses therefor.

专利号:US-11999757-B2
优先权日:2017-11-01
标 题:Synthesis of boronate ester derivatives and uses thereof
发明人：BOYER SERGE HENRI; HECKER SCOTT J; VERZIJL GERARDUS K M; HERMSEN PETRUS J
权利人:MELINTA SUBSIDIARY CORP
摘要:Disclosed herein are methods for the preparation of boronate derivatives in the synthesis of antimicrobial compounds and uses thereof. Disclosed herein includes method of making a compound of Formula (B) by reducing the ketone group of the keto-ester compound of Formula (A), and the reduction can be performed using a Ruthenium based catalyst system or using an alcohol dehydrogenase bioreduction system.

专利号:US-2008125587-A1
优先权日:2006-05-25
标 题 :Synthesis of triazole compounds that modulate HSP90 activity
发明人：CHIMMANAMADA DINESH U; LEE CHI-WAN; JAMES DAVID; ZHANG SHIJIE; YING WEIWEN; CHAE JUNGHYUN; PRZEWLOKA TERESA
权利人:CHIMMANAMADA DINESH U; LEE CHI-WAN; JAMES DAVID; ZHANG SHIJIE; YING WEIWEN; CHAE JUNGHYUN; PRZEWLOKA TERESA
摘要:The present invention provides novel methods of preparing triazole compounds which inhibit the activity of Hsp90. One embodiment of the invention is directed to methods for preparing a triazole compound represented by the following Structural Formula: n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising the steps of: a) reacting an amide represented by the following Structural Formula: n n n n n n n n n n with a thionation reagent to form a thioamide; b) reacting the thioamide of step a) with hydrazine to form a hydrazonamide; c) reacting the hydrazonamide of step b) with a carbonylation or a thiocarbonylation reagent. n In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising reacting a compound of formula (IIA) n n n n n n n n n n with an oxidizing agent, thereby producing a compound of formula (IA). n The present invention is also directed to a method of preparing a compound or a tautomer thereof represented by the following Structural Formula: n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof. The method comprises the step of reacting a first starting compound represented by the following Structural Formula: n n n n n n n n n n in the presence of a mercuric salt, with a second starting compound represented by the following Structural Formula:

专利号:US-10730904-B2
优先权日:2012-11-14
标 题:Method for liquid-phase synthesis of nucleic acid
发明人：NONOGAWA MITSURU; NAGATA TOSHIAKI; SAITO HIDEKI; YASUMA TSUNEO
权利人:TAKEDA PHARMACEUTICALS CO
摘要:In this method, an oligonucleotide represented by formula (II) [wherein Y 1 , Q, Base, r and r′ are each as defined in claim 1 ] is prepared by using, as a synthesis unit, a novel nucleoside monomer compound represented by formula (I) [wherein X, R 1 , Y, Base, Z, Ar, R 2 , R 3 and n are each as defined in claim 1 ]. The novel nucleoside monomer compound is a nucleoside, the base moiety of which is substituted with an aromatic-hydrocarbon-ring-carbonyl or -thiocarbonyl group having at least one hydrophobic group. The method can dispense with column-chromatographic purification in every reaction, and enables base elongation not only in the 3′-direction but also in the 5′-direction, thus attaining efficient liquid-phase mass synthesis of an oligonucleotide.

专利号:US-6998484-B2
优先权日:2000-10-04
标 题:Synthesis of purine locked nucleic acid analogues
发明人：KOCH TROELS; JENSEN FLEMMING REISSIG
权利人:SANTARIS PHARMA AS
摘要:The present invention relates to a new method for the synthesis of purine LNA (Locked Nucleic Acid) analogues which provides a higher overall yield. The method comprising a regioselective 9-N purine glycosylation reaction followed by a one-pot nucleophilic aromatic substitution reaction of the 6-substituent in the purine ring and simultaneous nucleophile-induced intramolecular ring closure of the C-branched carbohydrate to form novel purine LNA analogues. The novel strategy is illustrated by the synthesis of the novel compound (1S,3R,4R,7S)-7-benzyloxy-1-methanesulfonylmethyl-3-(guanin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane which is easily converted into (1S,3R,4R,7S)-7-hydroxy-1-hydroxymethyl-3-((2-N-isobutyrylguanin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane after isobutyryl protection of the 2-amino purine group and subsequent substitution of 1-methanesulfonyl with benzoate, debenzoylation and debenzylation.